Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Executive Summary

As part of its strategy to offset the coming Humira patent cliff, AbbVie Inc. is looking to oncology as a "significant pillar of growth" going forward, a gambit CEO Richard Gonzalez says will benefit greatly from both the pipeline candidates and the solid tumor R&D engine his company will obtain in the $5.8bn purchase of Stemcentrx announced April 28.

Advertisement

Related Content

Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
AbbVie’s Cancer Expansion Is Paying Off
Stockwatch: Has Sentiment Left the Biopharma Sector?
ADC Therapeutics Raises $105m To Reach Pivotal Studies
Stockwatch: Is Biotech Investing A State Of Mind?
Was Rova-T Worth The High Price To AbbVie?
JnJ Not Sweating Remicade Biosimilar Approval
Venclexta Win Broadens AbbVie/Genentech CLL Positions
Humira Competition Dominates AbbVie Earnings
Merck Hep C Drug Zepatier OK'd

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel